About Geneos Therapeutics

Furthermore, clinical studies with immune checkpoint inhibitors such as anti-PD1/PDL1 molecules (Keytruda®, Opdivo®, Tecentriq®, Imfinzi™, Bavencio® and others) have shown that these treatments appear to work better in tumors that have a high mutational burden suggesting that neoantigen directed immune responses are important for their anti-tumor activity. Thus, the accumulating clinical evidence strongly points to the idea that developing tumor specific neoantigen-targeted immunotherapies is an attractive approach for treating cancer.

Geneos’ personalized immunotherapies use the patient’s own immune system to induce CD4 and CD8 T cells against the tumor. CD8 T cells are the killing machines of the immune system seeking and destroying the cancer cells. Furthermore, GT-EPIC™ treatments are designed to target tumors with both high and low mutational burden. Thus, if successful, GT-EPIC™ therapies could be potentially used to treat all tumor types.